Mizuho Securities Downgrades FibroGen (FGEN) to Neutral

April 7, 2021 6:30 AM EDT
Get Alerts FGEN Hot Sheet
Price: $21.56 +2.47%

Rating Summary:
    5 Buy, 8 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 4 | New: 24
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Mizuho Securities analyst Difei Yang downgraded FibroGen (NASDAQ: FGEN) from Buy to Neutral with a price target of $29.00.

The analyst comments "We are downgrading FGEN shares to Neutral, and reducing our PT from $72 to $29 as we see higher risk and uncertainty around timelines to regulatory approvals following the clarification of previously disclosed cardiovascular safety analyses on roxadustat. Clinical data previously shared with the scientific and investment community included post-hoc adjustments resulting in more favorable safety data. While new data presented using pre-specified criteria still support the benefit/risk profile of roxa, we were surprised by the news and believe this creates higher risk in the near term, and uncertainty around timelines to potential approval. An upcoming FDA Advisory Committee (AdCom) meeting scheduled for 07/15/21 is likely to be a key de-risking event for the company."

For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.

Shares of FibroGen closed at $25.50 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades

Related Entities

AdCom, FDA